<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01059669</url>
  </required_header>
  <id_info>
    <org_study_id>REK nr 241.08</org_study_id>
    <nct_id>NCT01059669</nct_id>
  </id_info>
  <brief_title>The Diagnosis of Chronic Pancreatitis</brief_title>
  <official_title>A Multimodal Approach to Diagnose Patients With Chronic Pancreatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Haukeland University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Bergen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Haukeland University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To develop a new standardized multimodal diagnostic approach to CP considering:&#xD;
&#xD;
      WP 1: Fat in faeces and functional testing; the combination of tests has to be easy to&#xD;
      practice, should take as little time as possible and discomfort for the patient has to be&#xD;
      minimized WP 2: Advanced ultrasonography and imaging modalities. The focus is on validating&#xD;
      standard parenchymal, contrast enhanced and functional ultrasound compared to a modern&#xD;
      imaging standard. (CT, EUS, MRI)&#xD;
&#xD;
      To evaluate the reliability and feasibility of these novel methods in healthy volunteers; AND&#xD;
&#xD;
      To compare findings in known severe CP patients and different stages of pancreatic&#xD;
      insufficiency in patients with CP.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      WP 1: Exocrine function testing&#xD;
&#xD;
      Aims:&#xD;
&#xD;
      Evaluating an endoscopic short test in patients with suspected pancreatic disease. Main focus&#xD;
      on Chronic pancreatitis. (Collaborations to other patient groups in other protocols and to a&#xD;
      group of healthy controls. )&#xD;
&#xD;
      Methods:&#xD;
&#xD;
      Secretintsimulated Endoscopic short test With duodenal sampling 30-45 minutes after secretin&#xD;
      stimulation. Measurement of duodenal enzymes and duodenal bicarbonate concentration.&#xD;
&#xD;
      Inclusion:&#xD;
&#xD;
      Consecutive patients referred to a specialist outpatient clinic under suspicion of CP.&#xD;
&#xD;
      End Points:&#xD;
&#xD;
      Duodenal bicarbonate and enzyme concentrations. CP diagnosis by Layer/ Mayo score.&#xD;
      Statistics: Simple comparishments of grpup means. Accuracy calculations by ROC curves.&#xD;
      Sensitivity/ specificity calculations.&#xD;
&#xD;
      Sample size: Power and number of patients at baseline are calculated based on the following&#xD;
      assumptions: The smallest difference between the pancreatic sufficient and the insufficient&#xD;
      groups rejecting the null hypothesis are estimated to 25% regarding peak bicarbonate in EST.&#xD;
      The worst case standard deviation is chosen 25%. Sample sizes of 14 patients in each group&#xD;
      are expected to give the desired power of at least 0.80. Sample size: At least 15 patients in&#xD;
      each group.&#xD;
&#xD;
      WP 2: Testing of Advanced ultrasound Methods&#xD;
&#xD;
      Aims:&#xD;
&#xD;
      Evaluate the diagnostic accuracy of transabdominal ultrasound (US) compared to CP diagnosis&#xD;
      by Layer/ Mayo score, Endoscopic ultrasound (EUS), previous CT/ MRI examinations and exocrine&#xD;
      pancreatic function.&#xD;
&#xD;
      Sample size:&#xD;
&#xD;
      Power and number of patients at baseline are calculated based on the following assumptions:&#xD;
      The smallest difference between the pancreatic sufficient and the insufficient groups&#xD;
      rejecting the null hypothesis are estimated to 35% regarding peak bicarbonate in traditional&#xD;
      criteria counting. (average 4 criteria vs average 2 criteria) The worst case standard&#xD;
      deviation is chosen 25%. Sample sizes of 14 patients in each group are expected to give the&#xD;
      desired power of at least 0.80.&#xD;
&#xD;
      Sample size for interobserver variation analysis: Calculated by the principles of A&#xD;
      Cantor(1). Assuming a relative error of 30% (Due to earlier observed large interobserver&#xD;
      variations in these studies) , a clinical relevant kappa of 0.50 the estimated sample size&#xD;
      must be above 44. We intended to include at least 60 patients with both US and EUS. In this&#xD;
      setting kappa values below 0.4 must be interpreted with caution.&#xD;
&#xD;
      Hypothesis:&#xD;
&#xD;
        -  US can demonstrate changes in CP&#xD;
&#xD;
        -  US can diagnose CP with good accuracy.&#xD;
&#xD;
        -  US can demonstrate minimal changes in CP&#xD;
&#xD;
        -  US findings have good agreement compared to CP&#xD;
&#xD;
        -  Changes by US correlate to severity by exocrine pancreatic function.&#xD;
&#xD;
      Inclusion criteria: : Consecutive adult patients (&lt;16 years) referred to a specialized&#xD;
      outpatient clinic with suspected chronic pancreatitis (CP) due to presenting symptoms or&#xD;
      classical CP characteristics based on previous diagnostic imaging.&#xD;
&#xD;
      Exclusion criteria:&#xD;
&#xD;
        -  Patients unable to give informed consent.&#xD;
&#xD;
        -  Patients who had undergone extensive pancreatic surgery&#xD;
&#xD;
      In protocol exclusions pre-analysis:&#xD;
&#xD;
        -  Subjects who did not fulfil the protocol for an adequate Mayo score&#xD;
&#xD;
        -  Subjects with insufficient US visualization of the pancreas due to obesity, repeatedly&#xD;
           overlying bowel air or other factors.&#xD;
&#xD;
      Methods:&#xD;
&#xD;
        -  Collection of clinical data and previous CT/ MRI examinations from electrical patient&#xD;
           journal. Nutritional screening with Height/ Weight/ BMI. Laboratory tests. Blood for DNA&#xD;
           in Biobank,&#xD;
&#xD;
        -  Exocrine function tests. Short endscopic secretintest/ Faecal Elastase&#xD;
&#xD;
        -  Transabdominal Ultrasound: On inclusion and repeated 1-2 times within 3 months.&#xD;
           Operators blinded to clinical data.&#xD;
&#xD;
      Registration of Rosemont criteria. Contrast enhanced ultrasound (CEUS) by Sonovue.&#xD;
&#xD;
      Endoscopic ultrasound: blinded to the results of the US. (Subjects offered conscious sedation&#xD;
      with intravenous midazolam and pethidine or fentanyl hydrochloride during the test procedure)&#xD;
      Pancreas Scan from head to tail. Parenchymal and ductal criteria registered.&#xD;
&#xD;
      Trial chronology:&#xD;
&#xD;
        1. In advance: Invited to participate. Written information in advance.&#xD;
&#xD;
        2. 1. Visit: Signed written consent. Anamnesis and nutritional score.&#xD;
&#xD;
           o Ultrasound and EST&#xD;
&#xD;
        3. 2. Visit: Information of result.&#xD;
&#xD;
           o Repeated ultrasound with registration of Rosemont criteria and CEUS&#xD;
&#xD;
        4. 3. Visit: EUS with Rosemont score.&#xD;
&#xD;
        5. 4. Visit: Follow up, Information of results. Plan further follow up and treatment.&#xD;
&#xD;
        6. Post analysis: Layer/ Mayo score. Rosemont/ traditional score of US and EUS&#xD;
&#xD;
      Endpoints:&#xD;
&#xD;
      CP diagnosis by Layer/ Mayo score Imaging scores: Traditional criteria count and Rosemont&#xD;
      weighted score. Exocrine function results Endocrine function results Nutritional status&#xD;
      results.&#xD;
&#xD;
      Statistical analysis:&#xD;
&#xD;
      Comparisons between groups are made using student t-tests or Mann-Whitney U-test as&#xD;
      appropriate.&#xD;
&#xD;
      Accuracy data calculated from receiver operator curves (ROC). 5% level of statistical&#xD;
      significance will be used. Interobserver variation for the separate criteria will be&#xD;
      calculated as Cohens kappa.&#xD;
&#xD;
      Reliability for the ordinal data will be calculated as intraclass correlation coefficients&#xD;
      (ICCs) in a random, two-way analysis. Data analyzed according to absolute agreement.&#xD;
&#xD;
      Agreement will be defined according to Landis and Koch: 0 = no agreement, 0 - 0.20 = slight&#xD;
      agreement, 0.21 - 0.40 = fair agreement, 0.41 - 0.60 = moderate agreement, 0.61 - 0.80 =&#xD;
      substantial agreement, and 0.81--1 = almost perfect agreement. A clinically relevant&#xD;
      agreement usually requires a value &gt;0.5.&#xD;
&#xD;
      Inclusion period: Starting from des 2009.&#xD;
&#xD;
      Reference List&#xD;
&#xD;
      1. Cantor A. Sample-Size calculations for Cohens Kappa. Psychological Methods 1996;1:150-153.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2009</start_date>
  <completion_date type="Anticipated">August 2020</completion_date>
  <primary_completion_date type="Anticipated">August 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Development of pancreatic insufficiency</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak enzyme Concentration IE</measure>
    <time_frame>5 Years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>development of diabetes</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of pain</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>weight loss</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>peak amylase</measure>
    <time_frame>5 Years</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>lipase peak IE</measure>
    <time_frame>5 Years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Classical score US</measure>
    <time_frame>5 Years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Rosemont score US</measure>
    <time_frame>5 Years</time_frame>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Chronic Pancreatitis</condition>
  <arm_group>
    <arm_group_label>Patients</arm_group_label>
    <description>Patients with suspected Chronic Pancreatitis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <description>Healthy controls</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>diagnostic test</intervention_name>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Patients</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Pankreatic juice Duodenal tissue Blood&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patient with suspected chronic pancreatitis age 18-67 years&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The patients will be included from the Department of Medicine at Haukeland University&#xD;
             Hospital in Norway. The Marseille-Rome diagnostic criteria will be used. Patients will&#xD;
             be scored according to the Layer score. The symptoms should be unrelated to other&#xD;
             systemic diseases.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Personality disturbances and alcohol consumption 24 hours prior to the study. Any&#xD;
             other diseases and drugs associated with malabsorption; pregnancy or lactating women;&#xD;
             heart disease or allergy against MR or ultrasound contrast agents.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Georg Dimcevski, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Haukeland University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Georg Dimcevski, M.D</last_name>
    <phone>55972903</phone>
    <email>dgeo@helse-bergen.no</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gilja Odd Helge, Professor</last_name>
    <phone>55975000</phone>
    <email>odhg@helse-bergen.no</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Haukeland University Hospital</name>
      <address>
        <city>Bergen</city>
        <zip>5021</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Georg Dimcevski</last_name>
      <phone>55972903</phone>
      <email>dgeo@helse-bergen.no</email>
    </contact>
    <investigator>
      <last_name>Georg Dimcevski, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <study_first_submitted>January 29, 2010</study_first_submitted>
  <study_first_submitted_qc>January 29, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 1, 2010</study_first_posted>
  <last_update_submitted>August 17, 2016</last_update_submitted>
  <last_update_submitted_qc>August 17, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Haukeland University Hospital</investigator_affiliation>
    <investigator_full_name>Georg Gjorgji Dimcevski</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Chronic pancreatitis</keyword>
  <keyword>Pain</keyword>
  <keyword>Exocrine insufficiency</keyword>
  <keyword>Diabetes</keyword>
  <keyword>Nutrition</keyword>
  <keyword>Ultrasound</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatitis</mesh_term>
    <mesh_term>Pancreatitis, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

